How Should Registration Dossiers Be Prepared for Medical Device Registration in Japan?

Key Summary

To prepare registration dossiers for medical device registration in Japan, a company should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local representative, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission so that the project timeline is not extended by unclear classification, incomplete dossiers or undefined authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market dossiers can be reused.

Registration in a target market usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, deficiencies or rework are likely to arise in areas such as model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding dossiers country by country.

This article is compiled from AIMEILI registration practice resources, the medical device international registration knowledge base and public regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the actual product documentation base.

Published: 15 July 2026, 18:23  |  Updated: 15 July 2026, 18:23

This FAQ addresses the questions companies most need to resolve in practice regarding international medical device registration, dossier preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Dossiers and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-up Questions
• Further Reading
• Scope and Limitations

Applicable Scenarios and Core Questions

Companies searching for how to prepare registration dossiers for medical device registration in Japan are usually not looking for a conceptual explanation. They want to judge whether their existing documentation can support a submission in the target market, whether a local representative or authorized representative is required, why timelines become extended, and which issues could affect the launch plan. Behind this question are usually several connected topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first turn the core technical file, quality system evidence, performance verification, clinical evidence, labelling and instructions for use into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the product's intended use, mechanism of action, use scenario, mode of body contact, duration of use, whether it is sterile, whether it is powered, and whether it contains software or has IVD attributes, and then determine the risk class and the submission pathway. Once the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains the documentation required for certificate renewal. If these issues are handled vaguely in a commercial contract only, market control can easily be affected later.

Dossiers and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating domestic NMPA documentation and submitting it directly, without reorganizing the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local representative purely on the basis of a sales partnership, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and the claims in the registration dossier, leading to deficiencies or post-market compliance risk.
• Failing to plan for multi-country document reuse in advance, so that every country requires a separate effort and both cost and timelines are amplified.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, the model and specification matrix and the intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the duties, fees, certificate control and exit mechanism of the local representative or authorized representative.
• Establish a target country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to understand target market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter multiple countries, building one clear core technical file and evidence matrix first and then converting it to each country's requirements is usually faster and more stable than supplementing documents country by country, and it also supports subsequent changes and certificate renewals more effectively.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated deficiencies, representative communication problems and post-market maintenance issues, even if the documentation appears extensive.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it stands. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target market and product list have been confirmed. The earlier the gap assessment is completed, the earlier retesting, translation, label adjustments and representative selection can be arranged.

Why does the choice of local representative affect registration quality?

A local representative usually participates in registration communication, changes, certificate renewal and post-market event handling. Unclear allocation of duties and rights affects certificate control and the stability of the market afterwards.

Project Execution Recommendations

When executing this type of registration project, companies should set up a project ledger that manages the product list, model and specification matrix, registration pathway, document owners, translation status, testing status, local representative communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

For companies that already have registrations in several countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supported by additional explanations for a given country. In particular, labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must be kept at consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish the documentation gap assessment table.
• Define the local representative and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, model and specification list, or instructions for use version do not match the test reports, additional explanations may be requested even where a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping the product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiencies, particularly for projects involving simultaneous submissions in several GHWP member states or several product families.

Localization Conversion and Representative Responsibilities

Target market registration projects typically involve arrangements with a local representative, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market afterwards.

Labels, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance, so that once a manufacturing address change, model extension, instructions for use update or representative replacement occurs, the certificate becomes disconnected from actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency for a single country registration, but also the development of a repeatable overseas compliance capability, which reduces the cost of starting documentation from scratch each time a new market is entered.

Further Reading

• Previous: What should be done when quality system evidence is inconsistent for medical device registration in Korea?
• Next: How is product classification determined for medical device registration in Japan?

Recommended reading

• How should a local representative be selected for medical device registration in Brazil?
• How are authorized representative responsibilities divided for medical device registration in Brazil?
• Why do medical device registration timelines in Brazil become extended?
• What are the common reasons for dossier deficiencies in medical device registration in Brazil?
• How should post-market surveillance be conducted for medical device registration in Brazil?
• When must a registration change be filed for medical device registration in Brazil?

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: Official regulatory authorities, international organizations, standards organizations and public regulatory materials are prioritized; industry media and project experience are used only as supporting references.

Scope: This article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions or legal advice.